接收和风险分类的逻辑模型,为妇女生前和生后
Sandra Cristina de Souza Borges Silva1, Paula Soares Brandão2, Gisela Cordeiro Pereira Cardoso3
1Universidade do Estado do Rio de Janeiro, Faculdade de Enfermagem, Departamento de Enfermagem Materno-infantil, Rio de Janeiro, RJ, Brazil.
Revista da Escola de Enfermagem da U S P
|February 5, 2024
概括
开发了一种经过验证的逻辑模型,用于接受和风险分类,用于高风险的孕产妇护理前/阴. 该模型实现了高内容有效性,有助于临床决策.
科学领域:
- 产科和妇科 产科和妇科
- 医疗保健管理的管理
- 临床护理 临床护理
背景情况:
- 孕前和孕后对母亲的健康构成重大风险.
- 在高风险的孕产妇环境中,有效的风险分类和接待协议至关重要.
- 标准化模型可以改善患者管理和结果.
研究的目的:
- 为了验证一个逻辑模型的接收和风险分类量身定制为妇女生前/生.
- 加强分娩医院高风险怀孕的系统管理.
主要方法:
- 采用定量方法的评估研究.
- 逻辑模型的系统阐述和验证,包括范围审查和Donabedian模型.
- 内容验证指数 (CVI) 由12名专家利益相关者进行评估.
主要成果:
- 逻辑模型已成功构建,解决了已识别的临床问题.
- 实现了0.99的高内容验证指数,在24个项目上达成协议.
- 利益相关者对结构和过程要素之间的相关性提供了有价值的意见.
结论:
- 经过验证的逻辑模型证明了接受和风险分类的高内容有效性.
- 这种工具可以显著支持高风险产妇单位的管理人员的决策.
- 该模型的实施有可能改善患有妊娠前/妊娠前的妇女的护理.
更多相关视频
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
7.1K
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
826
相关概念视频
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).